cgrp calcitonin gene related peptide involved in central and peripheral sensitization during inflammation and nerve injury - Erenumab Calcitonin Gene Understanding Calcitonin Gene-Related Peptide (CGRP) and Its Role in Migraine

Calcitoningene-relatedpeptidemigraine Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, has emerged as a significant player in various physiological processes, most notably in the understanding and treatment of migraine.Calcitonin gene-related peptide(CGRP) isinvolved in central and peripheral sensitization during inflammation and nerve injury. This peptide, belonging to the calcitonin family, is produced by neurons in both the central and peripheral nervous systems. Its discovery approximately 30 to 40 years ago, stemming from alternative RNA processing, has paved the way for groundbreaking advancements in medical research and therapeutic interventions.

The Multifaceted Functions of CGRP

While CGRP is widely recognized for its association with migraine, its functions extend beyond this. It is a potent vasodilator, meaning it helps to expand blood vessels, which plays a role in regulating blood pressure. Research indicates that CGRP is also involved in central and peripheral sensitization during inflammation and nerve injury, highlighting its broader role in pain pathways. Furthermore, studies have explored the calcitonin gene-related peptide system's impact on the gastrointestinal tract and even its beneficial effects on the cardiovascular system, particularly in relation to exercise. The neuropeptide CGRP alpha is one of the two isoforms identified in humansCalcitonin gene related peptide in migraine.

CGRP and the Pathophysiology of Migraine

The link between calcitonin gene-related peptide and migraine is substantialCGRP mAbs target and block a chemical called calcitonin gene-related peptide (CGRP). CGRP is known to be associated with migraine attacks.. It is understood to be deeply involved in several of the pathophysiologic processes underpinning migraine attacks. Specifically, CGRP is found at the very centers of migraine processes, both centrally and peripherally作者：J Versijpt·2025·被引用次数：39—Since 2018, monoclonal antibodies (mAbs) targeting theCGRPpathway are available for migraine prevention. The approval of these drugs marks a .... Its release during a migraine attack is thought to contribute to the throbbing pain and other associated symptoms by causing vasodilation of cranial blood vessels and promoting neurogenic inflammation. This understanding has revolutionized how migraine is approached, shifting focus from merely managing pain to targeting the underlying mechanismsCalcitonin Gene Related Peptide,CGRP(alpha), human ...Calcitonin gene-related peptide(CGRP) is a 37-amino acid neuropeptide produced by tissue specific ....

Therapeutic Interventions Targeting CGRP

The growing body of evidence linking CGRP to migraine has spurred the development of novel therapeutic strategies. CGRP inhibitors and CGRP receptor antagonists, commonly known as gepants, represent a significant breakthrough in migraine prevention and treatment2023年4月13日—Calcitonin gene-related peptide(CGRP) inhibitors block the effect ofCGRP, which is a small protein that is highly prevalent in the sensory .... These medications work by blocking the action of CGRP or its receptor, thereby interrupting the cascade of events that lead to a migraineCalcitonin Gene Related Peptide(CGRP) stands forcalcitonin gene-related peptide, and it is a protein that is released around the brain..

Since 2018, monoclonal antibodies (mAbs) targeting the CGRP pathway have become available for migraine prevention. These CGRP monoclonal antibodies specifically target and block the calcitonin gene-related peptide.Calcitonin gene-related peptide receptor antagonist The development of these calcitonin gene-related peptide drugs marked a paradigm shift, moving the focus from acute treatment of attacks to more effective preventive strategies.CGRP mAbs target and block a chemical called calcitonin gene-related peptide (CGRP). CGRP is known to be associated with migraine attacks. Clinical trials have demonstrated their efficacy in reducing migraine frequency and severity.

Another class of drugs includes CGRP receptor antagonists, which bind to the calcitonin gene-related peptide receptor and prevent CGRP from exerting its effects. These CGRP antagonists offer an alternative mechanism of action for individuals who may not respond to or tolerate other treatments. The precise timing of effect onset after restarting anti-CGRP (or CGRP receptor) therapies is an area of ongoing research.

Future Directions and Ongoing Research

The exploration of calcitonin gene-related peptide continues to expand. Researchers are investigating its role in other neurological conditions and pain syndromes. The intricate calcitonin gene-related peptide system is a subject of continued study, with ongoing efforts to refine existing therapies and discover new applications. The calcitonin gene-related peptide receptor and its interactions remain a key focus for understanding and developing more targeted treatments作者：IM Bell·2014·被引用次数：90—Calcitonin gene-related peptide(CGRP) is a potent neuromodulator and vasodilator. It has been implicated in the pathogenesis of migraine by a number of .... The field of calcitonin gene-related peptide-targeted therapy in migraine is dynamic, with new research and clinical insights emerging regularly.

In summary, calcitonin gene-related peptide (CGRP) is a crucial neuropeptide with diverse physiological roles. Its significant involvement in the pathophysiology of migraine has led to the development of innovative CGRP-targeted therapies, offering new hope and improved management strategies for individuals suffering from this debilitating condition. The ongoing research into calcitonin gene-related peptide promises further advancements in our understanding and treatment of various health issues.Calcitonin Gene Related Peptide Receptor - an overview